Background: Varenicline has been found to decrease alcohol-motivated behaviors. Recent warnings regarding aversive events associated with varenicline used in conjunction with alcohol warrant further investigation into the safety of the drug when combined with alcohol. The purpose of this preliminary investigation was to examine the effect of combining varenicline with a high, fixed dose of alcohol on subjective reactivity and cognitive function in adults with alcohol use disorders (AUDs).
R
ECENT PRECLINICAL AND human laboratory studies suggest that the nicotinic acetylcholine receptor (nAChR) system may be a promising therapeutic target for reducing alcohol-motivated behaviors. Varenicline (Chantix) (Pfizer, New York, NY), a partial agonist of a4b2 nAChRs and a Food and Drug Administration (FDA)-approved smoking cessation aid, has been found to reduce alcohol selfadministration (Kamens et al., 2010; Steensland et al., 2007; Wouda et al., 2011) and cue-induced reinstatement to alcohol seeking (Wouda et al., 2011) in rodents. In humans, varenicline has primarily been tested at the 2 mg/d dose when assessing the effects of varenicline on drinking behaviors. We demonstrated that varenicline reduced alcohol consumption compared with placebo in heavy-drinking smokers, and decreased the subjective reinforcing effects of alcohol following a priming drink (McKee et al., 2009) . Subsequent studies have also shown that varenicline decreased alcohol intake and alcohol craving in heavy-drinking smokers and alcohol-dependent individuals (Mitchell et al., 2012; Plebani et al., 2013) . More recently, a multisite randomized, placebo-controlled clinical trial of 2 mg/d varenicline in smokers and nonsmokers meeting criteria for alcohol dependence demonstrated that varenicline attenuated alcohol craving, number of heavy-drinking days, and drinks per day compared with placebo (Litten et al., 2013) .
While varenicline has demonstrated efficacy for the treatment of alcohol use disorders (AUDs), recent FDA warnings regarding aversive events associated with varenicline used in conjunction with alcohol (Food and Drug Administration, 2015) warrant further investigation into the safety of the drug for the treatment of AUDs. The new FDA warnings indicate that individuals who drink alcohol while taking varenicline may experience increased drunkenness and unusual or aggressive behavior (Food and Drug Administration, 2015) . To date, there are no fixed-dose alcohol studies combining varenicline with alcohol in those with AUDs. The primary goal of this investigation was to examine the effect of combining varenicline with a fixed, high dose of alcohol on craving, intoxication, perceptual motor response, and executive cognitive function over the ascending and descending limbs of the blood alcohol curve in smokers and nonsmokers who meet criteria for AUDs.
While the recent FDA warnings are indicative of increased impairment while taking varenicline in conjunction with alcohol, in studies of smokers, results demonstrate that 2 mg/d varenicline improves and quickens cognitive function. Abstinent smokers taking varenicline showed greater improved sustained attention and working memory compared with placebo (Patterson et al., 2009) . Similarly, highly dependent smokers taking varenicline demonstrated greater performance on the visual N-back working memory task, and this was associated with an increase in working memory-related brain activity after 3 days of abstinence . Varenicline has also been shown to speed reaction time on measures of attention in nicotine-deprived smokers (Ashare and McKee, 2012) . Independent of smoking, healthy subjects also demonstrate enhanced effects on working and declarative memory following a short-term, low-dose (up to 1 mg/d) varenicline regimen (Mocking et al., 2013) .
However, some preclinical findings suggest that lower doses of varenicline may potentiate an alcohol effect. Lower doses (0.3 and 0.5 mg/kg) produced a slight, although nonsignificant increase in alcohol self-administration (Steensland et al., 2007; Wouda et al., 2011) and alcoholseeking (Wouda et al., 2011) . This effect was observed in a more recent study on alcohol-primed behaviors such that 0.3 mg/kg varenicline gave rise to a nonsignificant increase on alcohol responding (Randall et al., 2015) . We have recently completed the first study on the effects of lowering the dose of varenicline on alcohol self-administration in individuals with AUDs (Verplaetse et al., 2016) , the parent study to the present investigation. We found a modest effect of varenicline (2 mg/d) on reduced alcohol consumption and craving, but no dose-ranging effect of varenicline at the doses tested (1 and 2 mg/d) (Verplaetse et al., 2016) .
For the current preliminary investigation, we examined the effect of varenicline (0, 1 and 2 mg/d) in combination with alcohol (0.08 g/dl vs. a no-alcohol control beverage) on craving, subjective intoxication, perceptual motor response, and executive cognitive function. We hypothesized that 1 and 2 mg/d varenicline (vs. placebo) would reduce craving and subjective intoxication following alcohol consumption (McKee et al., 2009 ). Based on work in smokers and nonsmokers demonstrating that varenicline improves cognitive function Mocking et al., 2013; Patterson et al., 2009) , we predicted that varenicline would improve cognitive function overall. It was unknown what effect varenicline would have on alcohol-related impairments in cognitive function and perceptual motor tasks.
MATERIALS AND METHODS

Participants
Participants were eligible if they were ≥21 years of age and were able to read and speak English. All participants met DSM-IV criteria for past 6 months alcohol abuse (n = 18) or alcohol dependence (n = 26), and met criteria for heavy drinking (>4 drinks per episode for women; >5 drinks per episode for men at least once per week; American Psychiatric Association, 1994). Exclusion criteria included illicit drug use (except for occasional cannabis use), past 30-day use of psychoactive drugs, treatment seeking for alcohol or smoking, current Axis I disorders (except for nicotine dependence or alcohol abuse), current suicidal or homicidal ideation, pregnant or nursing, or medical conditions contraindicating alcohol use (e.g., liver enzymes ≥39 normal) or varenicline administration (e.g., known allergy to varenicline), or subjects likely to exhibit clinically significant alcohol withdrawal during the study (Clinical Institute Withdrawal Scale Score ≥8).
Procedures
Eligibility Screening. Participants were consented for the parent study and the current protocol at the same time. Of the n = 60 subjects who completed the parent study, n = 44 elected to also complete the current protocol. Briefly, in the parent study, varenicline was titrated to steady-state levels over 7 days, and participants then completed a single laboratory session examining alcohol self-administration (Verplaetse et al., 2016) . Following the self-administration session, participants who enrolled in the present investigation were maintained at steady-state varenicline levels for an additional 3-week period. During this 3-week period, participants completed 2 laboratory sessions as detailed below. The Human Investigation Committee of Yale University approved this study. Smokers and nonsmokers meeting criteria for AUDs were included in the present investigation. Smokers were daily smokers, smoking more than 5 cigarettes per day over the past year. Nonsmokers had not used any tobacco products over the past year.
Medication. The medication condition was double blind and placebo controlled, and was assigned in the parent varenicline study. Randomization to varenicline (1 or 2 mg/d) or a matching placebo (0 mg/d) was stratified by sex and smoking status. In the parent study, varenicline was titrated to steady-state levels over 7 days. Medication compliance was monitored with pill counts and riboflavin marker. Participants were maintained at steady-state levels for an additional 3-week period while they completed the 2 laboratory sessions (alcohol vs. control beverage), scheduled 1 week apart during weeks 2 and 3. Further methodological details can be found in the parent study (Verplaetse et al., 2016) .
Laboratory Sessions. Participants attended a 2-hour practice session scheduled during the week before their first laboratory session. The purpose of this practice session was to familiarize the subjects with the assessment battery. After the practice session, each subject completed 2 randomly assigned fixed-dose laboratory sessions (alcohol vs. control beverage). Sessions were approximately 9 hours in length. See Table S1 for a complete timeline of laboratory procedures. Reports of possible side effects from varenicline were evaluated in the parent study, which found all side effects to be minimal and mild (Verplaetse et al., 2016) .The laboratory session began at 9:00 AM, and baseline assessments of breath alcohol, breath carbon monoxide (CO), urine drug screen, urine pregnancy screen, vitals, height, and weight were obtained. Alcohol withdrawal was assessed, and pill counts and timeline follow-back information for alcohol and tobacco were obtained. Participants provided a urine sample to test for the riboflavin marker. If participants tested positive for alcohol, drug use, alcohol withdrawal, or pregnancy, they did not complete the laboratory sessions. Varenicline (0.5 or 1.0 mg) or placebo was administered at 9:30 AM followed by a standardized breakfast. To ensure that participants were not nicotine deprived during the session, smokers were provided with 15-minutes smoke breaks every 2 hours for 15 minute. Smoke breaks occurred at 11:15 AM and after the assessments occurring at +60, +180, and +300 minutes after alcohol consumption. Regular smoke breaks were provided in order to test smokers in a non-nicotine-deprived state, as nicotine deprivation in dependent smokers is known to reduce cognitive performance (Shiffman et al., 1995; Snyder et al., 1989) . Assessment Battery. At 11:30 AM, subjects completed the baseline assessment battery. The baseline assessment battery included breath alcohol concentration (BrAC), subjective reactivity, measures of cognitive function, perceptual motor response, physiologic reactivity, and adverse effects. Subjective reactivity was assessed using the Alcohol Urge Questionnaire (AUQ) (Bohn et al., 1995) and the Alcohol Effects Scale (AES) (Schuckit, 1984) . AUQ is a self-report measure assessing the desire for a drink, the expectation of positive effects from drinking, and the inability to avoid drinking if alcohol was available. AES is a self-report measure assessing subjective intoxication, high, like, rush, and feel-good from alcohol. AUQ and AES used Visual Analogue Scale with a range of 1 to 100. Cognitive function was measured using the Continuous Performance Task (CPT) (Beck et al., 1956) , the Digit Symbol Substitution Task (DSST) (McLeod et al., 1982) , and the N-back task (Conway et al., 2005) . The CPT assesses attention and response inhibition, and main outcomes were percent omission (the number of times the target was presented, but the subject did not respond) and commission (the number of times the subject responded, but no target was presented) errors in response to go and stop targets. The DSST assesses associative ability and learning, and main outcomes were the number of attempts and successes on a task in which a random digit appears on a computer screen and subjects use the numeric keypad to reproduce a geometric pattern associated with the digit. The N-back task assesses working memory by requiring subjects to respond to whether a letter is identical to the one presented n letters back, and main outcomes were number correct and total time to complete the task. Two N-back versions were completed (N-back 1 and N-back 2). The Pursuit Rotor task (Fillmore, 2003) assesses perceptual motor performance, and the main outcome was percent of time on target on a task in which subjects track a moving visual target on a computer screen by moving the computer mouse so that the crosshair sight is on the moving target. Heart rate and systolic and diastolic blood pressure were also measured using Dinamap (Critikon, Tampa, FL) for continuous heart rate and blood pressure measures. The battery was provided in a set order and took 30 minutes to complete.
Alcohol Administration. Subjects were told that they were consuming either alcohol or a nonalcohol control beverage by research staff. Subjects were informed of the beverage condition to increase the ecological validity of the manipulation. The purpose of the nonalcoholic beverage control group was to control for the repeated administrations of each task in order to highlight effects specific to alcohol. A second blinded research staff member conducted the laboratory sessions. For the alcohol session (order counterbalanced), subjects were given a fixed dose of alcohol (0.08 g/dl) at 12:15 PM. The alcohol beverage was designed to raise blood alcohol levels (BALs) to 0.08 g/dl of alcohol and consisted of 1 part 80 proof liquor of the subject's choosing to 3 parts mixer chosen from a selection of equicaloric, noncaffeinated, noncarbonated drinks. The amount of alcohol in the drink was based on a formula that takes into account gender, age, height, and weight of each subject (Watson, 1989) . The dose was divided into 2 glasses. Subjects had 5 minutes to consume each drink and a 5-minute rest period in between each drink. We have used this exact procedure previously (McKee et al., 2010) to successfully administer a dose of 0.08 g/dl. This procedure was originally adopted from colleagues (2002, 2011b) . Peak BALs are achieved within 60 minutes with levels declining over the next 5 hours. The nonalcohol control beverage used the same mixer and total volume as the alcohol beverage. Lunch was provided after the +120 time point. At 6:00 PM, transportation home was provided if the subject's BrAC did not reach 0.00%.
Time of Assessments. BrACs were assessed at baseline and at 15, 60, 120, 180, 240, and 360 minutes following alcohol consumption. CO levels, alcohol craving, subjective effects of alcohol (intoxication), objective effects of alcohol (cognitive function), physiologic measures (systolic and diastolic blood pressure, heart rate), and potential adverse effects were assessed at baseline, as previously described, and at 15, 60, 120, 180, 240, and 300 minutes following alcohol consumption.
Statistical Analysis
Baseline characteristics were compared across medication (0, 1, 2 mg varenicline) with analyses of variance (ANOVAs). If baseline differences existed, covariance adjustments were made as appropriate across planned analyses. Separate general linear models (GLM) were conducted for each measure of objective reactivity (cognitive function, perceptual motor response, physiologic reactivity, BrACs, adverse events) and for each measure of subjective reactivity (craving, intoxication). For each GLM, alcohol condition (0.08 g/dl, control beverage) and time (see study time points) were within subject factors and medication (0, 1, 2 mg/d varenicline) was a between subject factor. Contrasts examined 1 and 2 mg/d varenicline versus placebo within each time point and across beverage conditions. If the outcome differed by medication at the baseline time point (À45 minutes), the GLM was conducted with the À45 minutes values included as a covariate. Exploratory analyses were conducted to examine possible age, gender, smoking status, and Alcohol Use Disorders Identification Test effects across all planned analyses. These factors did not substantively change findings and were dropped from the final models for parsimony. A manipulation check was also conducted to determine whether alcohol had an effect on outcomes across the placebo groups in the alcohol versus control beverage session. Separate GLMs were analyzed with the placebo subjects only to confirm significant beverage by time effects. Presentation of the results is focused on main effects of medication and interactive effects of medication with time and/or beverage condition (see Supplementary Materials: Appendix S1 for presentation of main effects of time and beverage, and interactions of time and beverage effects).
RESULTS
Baseline Characteristics
Baseline characteristics did not differ between subjects who participated in the current study and those that only completed the parent study. Varenicline (1 and 2 mg/d) and placebo groups were well matched for baseline demographic variables, and drinking and smoking behavior (Table 1) .
Fixed-Dose Alcohol Versus Control Beverage Administration: Medication Effects
See Table 2 for a complete summary of GLM results and effect sizes. All effect sizes associated with significant and trend level GLM effects were calculated as Cohen's d, and all values were in the medium to large range (0.52 to 1.28). Within time point, contrasts of significant medication results are presented below (all ps < 0.05).
Manipulation Check. Limiting analysis to placebo subjects only, a high fixed dose of alcohol increased alcohol craving, subjective intoxication, and cognitive deficits during the alcohol session relative to the control beverage session (see Table 2 ).
Breath Alcohol Concentrations. As expected, BrACs increased after high fixed-dose alcohol consumption and steadily declined over the next 5 hours, F(1, 39) = 224.08, p < 0.001. Mean BrACs at the +60 time point were: grand mean = 0.058, SE = 0.002.
Alcohol Craving. Both 1 and 2 mg/d varenicline decreased alcohol craving at the baseline time point (Fig. 1A) . Varenicline did not demonstrate any main or interactive effects after controlling for this baseline difference.
Subjective Intoxication. Varenicline (1 mg/d) decreased subjective intoxication on the descending limb of the blood alcohol curve, and 2 mg/d varenicline decreased subjective intoxication at the +15 time point and over the course of the descending limb of the blood alcohol curve in the alcohol session only (medication by beverage by time interaction p = 0.04; see Fig. 2A, 2B) .
Cognitive Function. CPT: Varenicline (1 and 2 mg/d) decreased percent omissions at the +60 time point in the alcohol session only at a trend level (medication by beverage by time interaction p = 0.07; see Fig. 3A, 3B) . CPT commissions demonstrated a significant beverage by time by medication interaction (p = 0.02), but there were no significant within time point contrasts. DSST Attempts: At baseline, 1 and 2 mg/d varenicline increased DSST attempts (Fig. 1B) . Over the course of the alcohol and control beverage sessions, 1 and 2 mg/d varenicline increased DSST attempts relative to placebo (medication by time interaction p = 0.04; see Fig. 4A, 4B ). DSST Successes: At baseline, 1 and 2 mg/d varenicline increased DSST successes (Fig. 1C) . Over the course of the alcohol and control beverage sessions, 1 and 2 mg/d varenicline increased DSST successes relative to placebo at a trend level (medication by time interaction p = 0.06; see Fig. S1A , S1B). (Fig. 1D) . After equating for this baseline difference, 1 mg/d varenicline decreased N-back 1 total time at the +15-minute time point in the alcohol session and over the course of the control beverage session. Varenicline increased N-back 1 total time toward the end of the alcohol session only (medication by beverage by time interaction p = 0.05; see Fig. S2C, S2D ).
Perceptual Motor Function. At baseline, 1 mg/d varenicline increased average percent on target (Fig. 1E) . Over the course of the alcohol and control beverage sessions, 1 and 2 mg/d varenicline increased average percent on target relative to placebo at a trend level (medication by beverage by time interaction p = 0.1; see Fig. 5A , 5B).
Physiologic Measures. Systolic Blood Pressure: There were no significant medication effects for this outcome (ps > 0.05; see Fig. S3A, S3B) . Diastolic Blood Pressure: At baseline, 1 and 2 mg/d varenicline decreased diastolic blood pressure (Fig. 1F) . After equating for this baseline difference, 1 and 2 mg/d varenicline increased diastolic blood pressure relative to placebo for some time points in both the alcohol and control beverage sessions (medication by beverage by time interaction p = 0.02; see Fig. S3C, S3D ). Heart Rate: Varenicline increased heart rate over the course of the alcohol and control beverage sessions (medication by time interaction p = 0.05, medication by beverage by time interaction p = 0.08; see Fig. S3E, S3F ). Differences were most pronounced at the +60 time point. Education (p = 0.03); otherwise, no difference between groups using chi-square or ANOVA where appropriate. 
DISCUSSION
To our knowledge, this is the first preliminary fixed-dose investigation examining the effect of varenicline (1 and 2 mg/d) combined with high-dose alcohol on measures of subjective and objective reactivity in persons with AUDs. Overall, results demonstrated medication effects on subjective reactivity, cognitive function, and physiologic reactivity. Varenicline clearly attenuated alcohol-related increases in subjective intoxication and improved alcohol-related decrements in attention at a trend level. Prior to beverage administration, varenicline was found to reduce alcohol craving, and improve associative ability, working memory, and perceptual motor function. When these baseline medication differences were accounted for in the analysis, varenicline tended not to interact with alcohol to produce synergistic or additive effects for alcohol craving and some measures of cognitive function. There were few differences across the 1 and 2 mg/d doses. With regard to subjective reactivity, varenicline reduced alcohol craving relative to placebo, and attenuated increases in subjective intoxication at the peak and descending limb of the blood alcohol curve. For alcohol craving, these differences were present prior to beverage administration, suggesting that varenicline targeted tonic craving, and these differences persisted throughout both the alcohol and control beverage conditions (data not shown). This is consistent with findings from our parent study indicating that 2 mg/d varenicline reduced tonic alcohol craving during a priming drink period in heavy drinkers (Verplaetse et al., 2016) , and other studies demonstrating a reduction in alcohol craving and subjective alcohol effects following 2 mg/d varenicline in heavy-drinking smokers (Litten et al., 2013; McKee et al., 2009; Mitchell et al., 2012; Plebani et al., 2013) .
Varenicline improved cognitive function relative to placebo, and this effect was generally more pronounced in the 1 mg/d varenicline group. Varenicline improved associative ability and learning, improved working memory, and trended toward enhanced attention and perceptual motor performance with moderate effect size values (all with Cohen's d effect sizes in the moderate range). While varenicline attenuated alcohol-related decrements in attention, generally the effects of varenicline on improved cognitive function did not interact with alcohol. For associative ability and learning, working memory, and perceptual motor response, medication differences were present prior to beverage administration. However, varenicline tended to improve alcohol-related decrements in associative ability and perceptual motor function even after controlling for baseline differences. In contrast, varenicline increased total time on the Nback 1 toward the end of the alcohol session only after controlling for baseline differences that varenicline reduced Nback 1 total time. Further, smoking status did not significantly impact on the cognitive outcomes in the present investigation. Within our subset of smokers, a pattern of improved cognitive performance was not demonstrated based on time since last cigarette (data not shown). Overall, medication effects are consistent with prior work demonstrating that varenicline improves cognition in smokers and nonsmokers Mocking et al., 2013; Patterson et al., 2009) , and extends these findings by documenting that varenicline improves cognitive performance in individuals with AUDs and attenuates alcohol-related decrements in attention and perceptual motor response at a trend level.
Previous work with varenicline in smokers and nonsmokers indicates that the cognitive enhancing effects of varenicline may be due to its cholinergic properties, specifically the high affinity of varenicline to a4b2 nAChRs or, with lower affinity, to the a7 nAChR subtype. There has been much work focusing on nAChRs as a target for cognitive enhancement, particularly a7 Mocking et al., 2013) . Preclinical models support this hypothesis in that b2 and a7 knockout mice performed worse on cognitive tasks relative to their wild-type counterparts (Levin et al., 2009) . Similarly, an imaging study found that varenicline activates brain regions associated with working memory . It has been proposed (Mocking et al., 2013) that this activation may reduce cognitive deficits in working memory experienced as withdrawal symptoms during nicotine abstinence (Patterson et al., 2010) . Future work should continue to examine varenicline-alcohol interactions with regard to alcohol-related safety, and the mechanism behind varenicline's effects on cognitive function.
With regard to differences across active doses, 1 and 2 mg/d varenicline did not differ from each other on craving, subjective intoxication, and attention. There was a slight trend toward a dose-response for alcohol craving toward the end of the alcohol session but this effect was nonsignificant. Conversely, the 1 mg/d varenicline medication group performed better than the 2 mg/d medication group only at limited time points on measures of associative ability and perceptual motor function. The overall lack of differences between doses may indicate that varenicline may be equally efficacious at lower doses when given in combination with a fixed dose of alcohol. However, the parent study to the present investigation (Verplaetse et al., 2016) indicates that 2 mg/d had modest effects on alcohol intake and craving, but demonstrated no evidence supporting an effect of 1 mg/d varenicline on alcohol consumption or craving during a 2-hour ad libitum alcohol self-administration period. In the present investigation, there was no evidence for the lower, 1 mg/d varenicline dose to potentiate alcohol-related effects as suggested in some preclinical studies examining dose-ranging effects (Steensland et al., 2007; Wouda et al., 2011) .
Our findings are of immediate clinical relevance for the use of varenicline for AUDs given the recent FDA warnings on adverse events (e.g., increased drunkenness) (Food and Drug Administration, 2015) associated with varenicline-alcohol interactions. Although we observed minimal side effects and nonspecific effects of varenicline on physiologic reactivity, in the context of alcohol-related safety, our findings indicate that taking varenicline in combination with alcohol reduces alcohol-related cognitive impairment and decreases subjective intoxication; that is, individuals feel less intoxicated but also perform better on tasks measuring associative learning, attention, working memory, and perceptual motor function. From a clinical standpoint, our findings raise critical questions regarding the safety of individuals taking varenicline and drinking to intoxication. Individuals who feel less intoxicated may decide to continue drinking or underestimate the effects of alcohol on cognitive ability and decision making, potentially leading to increased alcohol-related consequences (e.g., driving under the influence, legal risk). However, findings from the parent study and prior established findings demonstrate that varenicline is associated with reduced alcohol consumption (Fucito et al., 2011; Litten et al., 2013; McKee et al., 2009; Mitchell et al., 2012; Verplaetse et al., 2016) , reduced alcohol craving (Schacht et al., 2014) , potentiated subjective aversive effects of alcohol (Childs et al., 2012) , and reduced cue-elicited brain activation in the medial orbitofrontal cortex (Schacht et al., 2014) . Alternatively, individuals who experience less alcohol-related cognitive impairment may be less likely to make poor or risky decisions while intoxicated.
Varenicline was well tolerated in our sample of heavy drinkers during the 2 fixed-dose laboratory sessions. Side effects were reported in the parent study (Verplaetse et al., 2016) , and mean severity ratings for each adverse event were reported as minimal to mild and did not differ across medication groups. Rates of dry mouth were greatest in the placebo group (35% placebo; 10% 1 mg/d varenicline; 10% 2 mg/d varenicline), whereas rates of insomnia were lowest in the 1 mg/d group (10% placebo; 0% 1 mg/d varenicline; 25% 2 mg/d varenicline). Further, no subject discontinued medication or required a dose adjustment as a result of adverse events. Overall, our preliminary findings indicate that combining varenicline with a high, fixed dose of alcohol appears to be safe and well tolerated in individuals meeting criteria for AUDs.
Similar to our parent study, there are study limitations. First, the present study sample consisted of non-treatmentseeking adults meeting criteria for alcohol abuse or dependence. The results may not generalize to treatment-seeking adults or drinkers without AUDs. Second, this investigation tested varenicline in combination with a single, fixed dose of alcohol. We did not test the safety of varenicline in combination with other fixed-dose concentrations of alcohol. However, the parent study examined the dose-ranging effects of varenicline on alcohol self-administration, and varenicline was well tolerated with minimal adverse events (Verplaetse et al., 2016) . Third, subjective and objective reactivity to alcohol while taking varenicline were only examined during the laboratory sessions. Thus, we do not know how craving, subjective intoxication, and cognitive function would be affected outside of the laboratory. Relatedly, we examined subjective intoxication as a single visual analog item. This may be problematic in that subjective intoxication may have bimodal (positive/drunk or bad/toxic) interpretations among study participants (King et al., 2011a) . Fourth, there were a large number of outcomes in this study for a limited sample size. We examined these outcomes as preliminary, and thus, the reported results were not adjusted for multiple comparisons. However, effect sizes for significant and trend level effects were all in the medium to large range. Fifth, the order of tasks within the assessment battery was provided in a fixed task order during each performance of the assessment battery, and it is unknown what effect this may have had on our results. Sixth, it is likely that BrAC levels peaked before the +60 minute time point. Our prior study using the same administration methods demonstrated that peak BrAC levels (0.078 g/dl) were achieved 45 minutes from the end of drinking (McKee et al., 2010) . Ideally, we would have assessed BrAC levels every 15 minutes over the first hour after alcohol intake to capture peak BrACs. The first assessment battery was administered during the ascending limb of the blood alcohol curve, and repeated BrAC measurements would have interfered with cognitive testing. However, we believe our dose manipulation was effective in capturing the effects of varenicline in combination with a fixed, high dose of alcohol. Finally, subjects were aware of the beverage condition prior to consuming either alcohol or the control beverage which may have impacted on our outcomes. In a realistic setting, subjects know whether they are consuming an alcoholic beverage or not, and we informed subjects of the beverage condition in order to increase the ecological validity of the study. Relatedly, we were not interested in examining effects in response to a placebo alcohol beverage, which is nearly impossible to mask at the dose used in this study (0.08 g/dl). The purpose of the nonalcoholic control beverage was to control for the repeated administrations of each task.
Collectively, our preliminary results support the clinical utility and safety of varenicline for the treatment of AUDs. In drinkers meeting criteria for AUDs, we found that 1 and 2 mg/d varenicline attenuated alcohol craving and subjective intoxication. We also found that varenicline increased cognitive functioning on tasks specific to attention, associative learning, and perceptual motor function. With the exception of subjective intoxication and attention, these effects were present prior to the consumption of alcohol, and effects of varenicline were generally not additive or synergistic with alcohol. Adverse events associated with varenicline-alcohol interactions were minimal and did not differ from the placebo group. These data suggest that varenicline continues to be a viable candidate for the treatment of AUDs.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article: Table S1 . Timeline of laboratory procedures. Appendix S1. Supplemental results: time and beverage effects. Fig. S1 . Baseline (À45 time point) adjusted mean (AESE) number of successes on the DSST following a high, fixed dose of (A) alcohol (0.08 g/dl) or (B) a control beverage by medication condition by time. Fig. S2 . Mean number correct (AESE) on the N-back 1 following a high, fixed dose of (A) alcohol (0.08 g/dl) or (B) a control beverage by medication condition by time. Baseline (À45 time point) adjusted total time (AESE) on the N-back 1 following a high, fixed dose of (C) alcohol (0.08 g/dl) or (D) a control beverage by medication condition by time. Fig. S3 . Mean (AESE) physiologic reactivity. Mean (AESE) systolic blood pressure following a high, fixed dose of (A) alcohol (0.08 g/dl) or (B) a control beverage by medication condition over the course of the alcohol curve; Baseline (À45 time point) adjusted mean (AESE) diastolic blood pressure following a high, fixed dose of (C) alcohol (0.08 g/dl) or (D) a control beverage by medication condition over the course of the alcohol curve; Mean (AESE) heart rate following a high, fixed dose of (E) alcohol (0.08 g/dl) or (F) a control beverage by medication condition by time.
